Jenny Ge

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised Delphix, a vendor of test data management software, on its acquisition by Perforce, a provider of solutions to enterprise teams requiring productivity, visibility and scale along the development life cycle.

Cooley advised Bridge to Life, an organ preservation and perfusion technologies supplier, on its sale of certain assets – including its EVOSS heart and lung and LifeCradle heart perfusion assets – to TransMedics.

Cooley advised Tmunity Therapeutics, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.

Cooley advised Comparably, a venture-backed employee review website – and the only platform showcasing workplace culture, salary and corporate brand reputation data – on its sale to ZoomInfo, a company focused on modern go-to-market software, data and intelligence. Lawyers Stephen Dunst, Dave Young and James Curtis Allen led the Cooley team advising Comparably.

Read more